Corcept Therapeutics (CORT) Cash & Equivalents (2010 - 2026)

Corcept Therapeutics has disclosed Cash & Equivalents across 17 years of filings, most recently posting $108.7 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $108.7 million, up 21.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $108.7 million (up 21.06% YoY), and the FY2025 annual result was $120.5 million, down 5.62% from the prior year.
• Cash & Equivalents came in at $108.7 million for Q1 2026 at Corcept Therapeutics, down from $120.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $299.9 million in Q1 2023 to a low of $35.3 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $120.5 million (2025), against an average of $119.0 million.
• Across the five-year window, Cash & Equivalents plunged 62.96% in 2022 and soared 387.68% in 2023, its largest moves.
• Corcept Therapeutics' Cash & Equivalents stood at $66.3 million in 2022, then jumped by 104.36% to $135.6 million in 2023, then decreased by 5.82% to $127.7 million in 2024, then slipped by 5.62% to $120.5 million in 2025, then slipped by 9.76% to $108.7 million in 2026.
• The last three Cash & Equivalents figures came in at $108.7 million (Q1 2026), $120.5 million (Q4 2025), and $125.1 million (Q3 2025), per Business Quant data.